| Company/Division name | GlaxoSmithKline |
| Parent company | GlaxoSmithKline |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2019 |
| Capital investment ($): | 100 |
| Country(ies) from which reshored: | United Kingdom |
| City reshored to: | Hamilton |
| State(s) reshored to: | MT |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | vaccine adjuvants |
| What domestic positive factors made reshoring more attractive? | Customer responsiveness improvement, Proximity to customers/market, Other, expansion of current production |
